Description
Created On: 2020-07-15
Record Count: 18
Primary Industries
- Drugs
- Disease
- HIV / AIDs
- Vaccine
- Therapeutic
- Immune
- Cancer
- DNA
- Proteins
- Genome
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 204321
AAV means an adeno-associated virus composed of a viral capsid comprising three proteins known as VP1, VP2, and VP3, wherein the genome is a single strand DNA molecule of approximately 4.5kb in size, flanked by inverted terminal repeats (ITRs) of approximately 145bp designated ITRs.
AAV Vector means a recombinant AAV where the approximately 4.5kb genome has been replaced by HIV sequences of interest under the control of appropriate regulatory sequences.
Licensor Licensed Patent Rights means all Patent Rights to the extent of the subject matter of such rights which claim AAV Vector compositions, methods of making AAV Vector compositions, or use of AAV Vector compositions, to the extent Controlled (but not owned) by Licensor as a result of being licensed to Licensor by a Third Party Licensor under one or more Third Party Agreements, and all improvements.
Licensor Patent Rights means all Patent Rights Controlled by Licensor to the extent of the subject matter of such rights which claim AAV Vector compositions, methods of making AAV Vector compositions, or use of AAV Vector compositions solely to the extent that such rights are owned, but not in-licensed, solely or jointly by Licensor as of the Initial Agreement Date, or claim priority to any such Patent Rights, or claim any invention conceived during the Development Period which conception arose, at least in part, from activities funded by Licensee under the Initial Agreement or this Agreement, and all improvements.
IPSCIO Record ID: 223152
Licensor Patent Rights means Patent Rights Controlled by Licensor to the extent of the subject matter of such rights that claim any invention which was conceived of during the Development Period which conception arose, at least in part, from activities conducted as part of the Development Program or through the use of Program Materials; and, which is reasonably necessary or useful for the Development, Manufacture and/or Commercialization of an AAV product.
AAV means an adeno-associated virus composed of a viral capsid comprising three proteins known as VP1, VP2, and VP3, wherein the genome is a single strand DNA molecule of approximately 4.5kb in size, flanked by inverted terminal repeats (ITRs) of approximately 145bp designated ITRs.
IPSCIO Record ID: 237242
Licensee-Controlled Inventions shall mean the inventions disclosed in the United States patents and foreign equivalents and United States and foreign patent applications listed and all divisions, continuations, continuations in part, reissues, or extensions thereof, any periods of marketing exclusivity relating thereto, and any letters patent that issue thereon. It is understood that certain of the Licensee-Controlled Inventions (the Licensed Licensor Rights) are owned by Licensor and are covered by one or more exclusive licenses or sublicenses to Licensee, directly or indirectly.
US 5,858,775 – Adeno-associated virus materials and methods
US 5,786,211 – Adeno-associated virus materials and methods
US 5,658,785 – Adeno-associated virus materials and methods
US 5,139,941 – AAV transduction vectors
Program Vaccines shall mean any AAV (adeno-associated virus) particle-based vector that contains an HIV-1 gene in the recombinant vector genome and that can act as a prophylactic vaccine against HIV-1.
Proprietary Technology shall mean any Background Technology to the extent it has not previously been disclosed in an issued patent or a published patent application. Background Technology shall mean: (i) the rights to make, use, sell, offer for sale, and import the Licensee-Controlled Inventions; (ii) all inventions (whether or not patented or patentable), know-how, techniques, cell lines, data, studies and results of studies and other proprietary information in the possession or control of Licensor at the Effective Date and at any time thereafter during the period in which Licensor remains a direct participant in the Research and Development Program, to the extent bearing upon the Program Vaccines, the Licensee-Controlled Inventions, the Program Inventions, or any of them within the Program Field (as and to the extent the Program Field exists during the period of such direct participation by Licensor); and (iii) know-how and other proprietary information in the possession or control of Licensee at the Effective Date and at any time thereafter during the period in which Licensee remains a direct participant in the Research and Development Program, to the extent useful for the practice of the Licensee-Controlled Inventions within the Program Field (as and to the extent the Program Field exists during the period of such direct participation by Licensee).
Work Plan and Budget shall mean the set of tasks, procedures, protocols, standards, budgets, and target time frames set forth, as such may be amended or supplemented by mutual written agreement of the parties from time to time.
Program Field shall mean the manufacture of one or more of the Program Vaccines through the use of the particular combination of Program Inventions and Background Technology as implemented by Licensor and Licensee under this Agreement during and in the course of the Research and Development Program (as the same may be supplemented or improved by or for Licensor with other inventions or technology from sources other than Licensor or Licensee), solely for distribution in the Public Sector, and the use, sale, offer for sale, and import of such Program Vaccines so manufactured in and to the Public Sector. I
The collaboration agreement is to develop a vaccine to prevent AIDS. The vaccine will utilize Targeted Genetics’ Adeno-Associated Viral Vectors (AAV ) to deliver HIV genes as a novel form of genetic immunization.
IPSCIO Record ID: 211877
In the asset purchase, the Seller agrees to sell, convey, transfer and assign to Buyer, and Buyer agrees to purchase from Seller, free and clear of any Encumbrances, all of Seller’s right, title and interest in and to the following properties, assets and rights:
(a) the Transferred Technology;
(b) the Assigned Patent Rights;
(c) the Transferred Equipment;
(d) all of Seller’s rights under that certain Exclusive Sublicense Agreement; and
(e) all rights of Seller to Actions and rights of Seller to sue at law or in equity.
Excluded Technology shall mean (i) any composition that is specific to a particular AAV Vector serotype or pseudotype and any data and other Technology that is specific to such a composition; any composition, method, process or other Technology that is specific to an AAV Vector comprising a particular gene; any composition, method, process or other Technology that is specific to a particular gene; any final formulation buffer for clinical delivery of an AAV Vector comprising a particular gene and any data or other Technology that is specific to such buffer; and any analytical method specific to product performance of an AAV Vector comprising a particular gene.
(iii) delivery of tgAAC94 as identified in Seller's regulatory filings as of the Closing Date which comprises the DNA sequence encoding the p75 TNFr receptor lg fusion protein, and
(iv) the delivery of RNAi using AA V Vectors for the revention or treatment of Hepatitis C.
IPSCIO Record ID: 291138
Group 2 License Grant. University hereby grants to Licensee and the Covered Affiliates for the term of this Agreement the worldwide right and license, with the right to grant sublicenses, to develop, have developed, make, have made, use, have used, import, have imported, sell, offer for sale and have sold University Licensed Products under the Group 2 Patents in all fields of use. Such right and license shall be non-exclusive to Licensee in the LSD Field. Subject to this Agreement, such right and license shall be exclusive to Licensee outside the LSD Field.
University hereby grants to Licensee and the Covered Affiliates for the term of this Agreement the worldwide right and license, with the right to grant sublicenses, to develop, have developed, make, have made, use, have used, import, have imported, sell, offer for sale and have sold University Licensed Products under the Group 3 Patents in in all fields of use. Subject to this Agreement, such rights and license shall be exclusive to Licensee.
US 6,475,769 – Methods and cell line useful for production of recombinant adeno-associated viruses
US 7,238,526 – Methods and cell line useful for production of recombinant adeno-associated viruses
Group 2 Patents means the following patents:
US 6,759,237 – Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
US 7,186,552 – Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
Group 3 Patents means
US 7,056,502 – Recombinant aav vectors with AAV5 capsids and AAV5 vectors pseudotyped in heterologous capsids
University Licensed Product(s) means products that in the absence of this Agreement would, where and when made, used, sold, or imported, infringe at least one issued claim or pending claim of University Patent Rights; and products that are made using a process or machine that in the absence of this Agreement would, where and when used, infringe at least one issued claim or pending claim of University Patent Rights. All University Licensed Products intended to deliver the same Gene shall be considered a single University Licensed Product for purposes of this Agreement.
University Patent Rights means those patents and patent applications listed in this Agreement and all foreign counterparts thereof, as well as continuation, continuation-in-part, provided that such continuation-in-part relates directly to existing patents or patent applications and not to any new matter, divisional and re-issue applications
thereof, together with any and all patents issuing thereupon or upon any foreign counterparts thereof; provided, however, that Licensee acknowledge that the invention relating to non-invasive delivery of transgenes into the bloodstream, which is disclosed in Example 6 of International Patent Application No. PCT/USO1/13000 (M2304PCT), and in a US CIP application No. 09/955,444 (N2605), was made at University following termination of the research under the Sponsored Research Agreement. Licensee hereby acknowledge that they have no rights in this invention relating to non-invasive delivery of transgenes into the bloodstream, as defined in these applications and divisionals, continuations, re-examinations, re-issues, and any foreign counterparts thereof, and any patents issuing therefrom. Licensee agree that they will not make or pursue any claims that this invention as so defined is or should have been part of the University Patent Rights.
Gene means any nucleotide sequence that is capable of encoding, or of causing or modulating the expression of, a proteiin, protein fragment, or other genetic element. For the purposes hereof, a Gene having 90% homology to that of another Gene, and which expresses essentially the same protein for at least one biological function, shall be considered the same Gene as such other Gene.
LSD Field means the prevention, treatment, or cure of lysosomal storage diseases whether by in vivo or ex vivo means (together with preparation, research, development, and attempts to do the foregoing).
Cancer Field means the prevention, treatment or cure of malignancies whether by in vivo or ex vivo means together with preparation, research, development, and attempts to do the foregoing).
TNFr/Inflammatory Field means the prevention, treatment, or cure of any disease or diseases in whole or in part through use or delivery of the TNFr Gene or any other Gene acting in the Inflammatory Pathway, whether by in vivo or ex vivo means (together with preparation, research, development, and attempts to do the foregoing).
IPSCIO Record ID: 244658
Licensor grants an exclusive, worldwide license under the Ad Interferon-beta Product Licensor Patents and the Ad Interferon-beta Product Technology to develop, research, make, have made, use, have used, sell, offer for sale, import and have sold the Ad Interferon-beta Product in the Cancer Field and the Beta Interferon Field .
For the Manufacturing License, Licensor will provide a transferable, limited license or subiicense as the case may be under the Licensor Technology and the Licensor Patents to manufacture such Clinical Vectors and Commercial Vectors to the extent necessary to enable Licensee to manufacture quantities of the Clinical Vectors and Commercial Vectors that otherwise would have been supplied by Licensor to Licensee under this Agreement, solely for use and application by Licensee for the uses and applications in the Territory that would be permitted under this Agreement with respect to such Clinical Vectors and Commercial Vectors purchased from Licensor.
Licensor grants a license, with right to grant sublicenses, under the Licensor Technology and the Licensor Patents to research, develop, manufacture, have manufactured, use, import, export, offer to sell or sell Products in the Territory.
Licensor grants a nonexclusive, worldwide license, with right to sublicense to Contractors permitted under this Agreement, to the Licensed Technology, other than the Applied Licensor Technology, as designated in the applicable Project Plan and Budget, and under any Licensor Patents, other than the Exhausted Licensed Patents and the Exempted Licensed Patents, as designated in the applicable Project Plan and Budget, which would, but for this license grant, be infringed by Licensees performance of its Development Tasks solely as necessary for performance of Licensees Development Tasks during and in the course of any approved Development Project.
In addition to the other rights granted under this Agreement, Licensor hereby grants an option to acquire a license, with the right to grant sublicenses, to Licensor Technology, that is not otherwise designated as Applied Licensor Technology in the applicable Project Plan and Budget, and under any and all Targeted Patents, that are not designated as Exhausted Licensor Patents or as Exempted Licensor Patents in the applicable Project Plan and Budget.
AAV Interferon-beta Product means a Product incorporating the Beta Interferon Gene and any AAV Vector as the delivery platform.
AAV Vector means an adeno-associated viral vector useful or potentially useful for the delivery of Genes to human cells.
Ad Interferon-beta Product means the Product incorporating the Beta Interferon Gene and an Ad Vector that is the subject of the Ad Interferon-beta Project.
Ad Vector means an adenoviral vector useful or potentially useful for the delivery of Genes to human cells.
Cancer Field means the treatment or prevention in humans of one or more cancers through the use or application of AAV Vectors or Ad Vectors.
IPSCIO Record ID: 275801
Licensed Product shall mean any HIV vaccine product other than the HIV Vaccine that cannot be developed, manufactured, used, or sold without infringing one or more Valid Claim under the Patent Rights.
The patents are titled: Polyvalent, Primary HIV -1 Envelope Glycoprotein DNA Vaccine, and, Polyvalent DNA and Protein Vaccines.
This technology is a DNA-based HIV vaccine that incorporates the 03-24 Technology and the 03-111 Technology. Invention disclosure number 03-24 is entitled Primary and Polyvalent IIlV-1 Envelope Glycoprotein DNA Vaccines. And HIV protein boost technology invention is referred to as 03-111.
New Vaccine shall mean any HIV vaccine other than the HIV Vaccine.
IPSCIO Record ID: 233458
The grant is replaced in its entirety with:
The University grants to Licensee exclusive licenses under Patent Rights to make, use, sell, offer for sale, and import Patent Products and Vaccine Adjuvant Product and to practice the Patent Method. Licensee is expressly prohibited from selling a Derived Product or Vaccine Adjuvant Product to any third party, except that Licensee may sell a Vaccine Adjuvant Product to the Third Party.
The University also grants to Licensee the right to issue sublicenses to third parties to make, use, sell, offer for sale, and import Patent Products and practice the Patent Method, provided Licensee retains current exclusive rights under this Agreement.
The University also grants to Licensee the right to issue sublicenses to the Third Party to make, use, sell, offer for sale, and import Vaccine Adjuvant product and practice the Patent Method, provided Licensee retains current exclusive rights under this Agreement.
The patents include Biologically Active Composition Having A Nanocrystalline Core; Human Immunodeficiency Virus Decoy; and, Targeted Transfection Nanoparticles.
The Drug Delivery Product means a Licensed Product, which would, were it used or sold in the United States, require marketing approval by an appropriate regulatory agency for the use in pharmaceutical preparations to facilitate the therapeutic delivery of drugs in humans.
Vaccine Adjuvant Product means a Licensed Product that, when added as part of a Vaccine Product, improves the immune response so that less of a Vaccine Product is needed to produce more antibodies.
Vaccine Product means a Licensed Product, which would, were it used or sold in the United States, require marketing approval by an appropriate regulatory agency for any preparation containing a suspension of dead, attenuated, or otherwise modified microorganisms, e.g. viruses, bacteria, or rickettsiae, or parts thereof, that is used to produce an immunity against a disease in humans or other animals by stimulating the production of antibodies.
Derived Product means any product that is made by using a composition of matter claimed under Patent Rights or by practicing the Patent Method to make a final product regardless of the number of steps in the process or the number and types of compositions of matter, e.g., intermediate compounds, that are involved in making the final product. A Derived Product also means any product that is made by using a composition of matter claimed under Patent Rights whether or not that composition of matter is directly incorporated or a part of the final product.
– a kit, composition of matter, material, product, or Derived Product;
– a kit, composition of matter, material, product, or Derived Product to be used in a manner requiring the performance of the Patent Method; or
– a kit, composition of matter, material, product, or Derived Product produced by the Patent Method;
The Excluded Field means any field other than a Vaccine Product, Drug Delivery Product, and Vaccine Adjuvant Product.
Patents are in fields of use initially pertaining to: (1) vaccine adjuvants; (2) vaccine constructs or combinations for use in immunization against herpes virus; (3) drug delivery systems; and (4) red blood cell surrogates.
IPSCIO Record ID: 275977
The Research and Development Program will involve the systematic design and development of the Program Vaccine for use in the Field. The scope and goals of the Research and Development Program are subject to modification.
Licensor grants the Licensee of Denmark a worldwide, nonexclusive, non sublicensable and nontransferable license during the Research Term to practice the Licensor Background Technology, the Licensor Patent Rights and the Joint Patent Rights, solely in connection with activities to be performed by Licensor under the Research and Development Program.
Licensor grants a worldwide, non-exclusive and nontransferable license, with rights to sublicense, under the Licensor Background Technology, the Licensor. Patent Rights and the Joint Patent Rights, to make, have made, use, sell, offer for sale and import Licensee-Combined Vaccines or the Program Vaccines.
IPSCIO Record ID: 273254
The '03-111 Technology – U. S. Patent Application Serial Number 60/503,907 (the '03-111 Patent Filing') covering an HIV protein boost technology invention referred to by University and Licensor as UMMC 03-111.
IPSCIO Record ID: 273729
The '03-111 Technology – U. S. Patent Application Serial Number 60/503,907 (the '03-111 Patent Filing') covering an HIV protein boost technology invention referred to by University and Licensee as UMMC 03-111.
IPSCIO Record ID: 294014
Adeno-associated viruses are small viruses that infect humans and some other primate species. They belong to the genus Dependoparvovirus, which in turn belongs to the family Parvoviridae.
Cystic fibrosis is a hereditary disease that affects the lungs and digestive system. The body produces thick and sticky mucus that can clog the lungs and obstruct the pancreas. Cystic fibrosis (CF) can be life-threatening, and people with the condition tend to have a shorter-than-normal life span.
IPSCIO Record ID: 192627
(a) Patent applications (including provisional patent applications and PCT patent applications) or patents listed, all divisions and continuations of these applications, all patents issuing from these applications, divisions, and continuations, and any reissues, reexaminations, and extensions of all these patents;
(b) to the extent that the following contain one or more claims directed to the invention or inventions disclosed in 2.6(a):
(i) continuations-in-part of 2.6(a);
(ii) all divisions and continuations of these continuations-in-part;
(iii) all patents issuing from these continuations-in-part, divisions, and continuations;
(iv) priority patent application(s) of 2.6(a); and
(v) any reissues, reexaminations, and extensions of all these patents;
(c) to the extent that the following contain one or more claims directed to the invention or inventions disclosed in 2.6(a): all counterpart foreign and U.S. patent applications and patents to 2.6(a) and 2.6(b), including those listed in Appendix A; and
(d) Licensed Patent Rights shall not include 2.6(b) or 2.6(c) to the extent that they contain one or more claims directed to new matter which is not the subject matter disclosed in 2.6(a).
U.S. Patent Application(s) or Patent(s):
(a) U.S. Patent Application Serial No. 09/986,618, filed November 9, 2001, now abandoned, entitled “Production of Adeno-Associated Virus in Insect Cells†[HHS Ref. No. E-325-2001/0-US-01];
(b) U.S. Patent No. 6,723,551, issued April 20, 2004, entitled “Production of Adeno-Associated Virus in Insect Cells†[HHS Ref. No. E-325-2001/1-US-01]; and
(c) U.S. Patent Application Serial No. 10/415,834, filed May 2, 2003, entitled “Production of Adeno-Associated Virus in Insect Cells†[HHS Ref. No. E-325-2001/2-US-02].
Licensed Products means (a) Supplied Materials and (b) tangible materials, which in the course of manufacture, use, sale, or importation, would be within the scope of one or more claims of the Licensed Patent Rights that have not been held unpatentable, invalid or unenforceable by an unappealed or unappealable judgment of a court of competent jurisdiction.
New Product means a product made using a Licensed Process but excluding Licensed Products.
Licensed Processes means processes, which in the course of being practiced, would be within the scope of one or more claims of the Licensed Patent Rights that have not been held unpatentable, invalid or unenforceable by an unappealed or unappealable judgment of a court of competent jurisdiction.
The Disease: Lipoprotein Lipase Deficiency
Genetic lipoprotein lipase (LPL) deficiency results in profound hypertriglyceridemia, which is associated with intense chronic abdominal pain, hepatosplenomegaly, eruptive xanthomas, lipemia retinalis, dyspnea, mono- or polyparesthesias, and memory loss. Prolonged elevations in plasma triglycerides (TG) also induce recurrent episodes of often lethal pancreatitis, chronic pancreatic insufficiency, and diabetes mellitus. Currently, no effective treatment for this disease exists. Patients must follow a strict low-fat diet. However, TG levels often remain above the critical threshold. Genetic LPL deficiency type I is a rare, autosomal recessive trait. Prevalence varies between 1 in 1,000,000 in the general population to 1 in 5,000 in French Quebec (a ‘founder effect’).
Acute intermittent porphyria (AlP) is an autosomal dominant inherited condition caused by mutations in the porphobilinogen deaminase (PBGD) gene. The PBGD gene is located on chromosome 11 q24.1 -24.2 and spread over fifteen exons. The protein encoded by this gene is a rate-limiting enzyme, the PBGD enzyme, in the haem synthetic pathway.
Parkinson’s disease (PD) is a progressive neurodegenerative disease, resulting in tremors, stiffness, slowness of movement, and lack of coordination. Patients are faced with a severely debilitating disease and a serious loss in quality of life. PD is caused by degeneration and death of nerve cells in a specific part of the brain known as the substantia nigra. These cells produce dopamine, a substance necessary for communication between nerve cells involved in the coordination of movement.
Licensee is building gene therapies using adeno-associated viral (AAV)-based vectors.
IPSCIO Record ID: 203266
Mydicar is a genetically targeted enzyme replacement therapy being studied for use in patients with severe heart failure. It is designed to increase the level of SERCA2a, a sarcoplasmic endoplasmic reticulum calcium (Ca2+) ATPase found in the membrane of the sarcoplasmic reticulum (SR). The SERCA2a gene is delivered to the heart via an adeno-associated viral vector.
IPSCIO Record ID: 273437
The Research and Development Program will involve the systematic design and development of the Program Vaccine for use in the Field. The scope and goals of the Research and Development Program are subject to modification.
Licensor grants a worldwide, nonexclusive, nonsublicensable and nontransferable license during the Research Term to practice the Licensor Background Technology, the Licensor Patent Rights and the Joint Patent Rights, solely in connection with activities to be performed by Licensee under the Research and Development Program.
Subject to the exercise by Licensee of the Combination Option or Option, Licensor grants to a worldwide, non-exclusive and non-transferable license, with rights to sublicense, under the Licensor Background Technology, the Licensor Patent Rights and the Joint Patent Rights, to use, sell, offer for sale and import Combined Vaccine or the Program Vaccine during the Term.
IPSCIO Record ID: 273253
Medical School hereby grants to Company and its Affiliates a non-exclusive, royalty-bearing license (with the right to sublicense) under its commercial rights in the Related Technology to develop, make, have made, use, and sell Licensed Products in the Field and Licensor hereby consents to such grant by Medical School.
Licensor hereby grants to Company and its Affiliates the right to acquire a non-exclusive, worldwide, royalty-bearing license (with the right to sublicense) to any Licensor Related Technologies. Licensor shall promptly disclose in writing to Company each of the Licensor Related Technologies at the time such technologies are acquired or licensed by Licensor. Licensor and Company shall negotiate in good faith the terms of the Licensor Related Technologies License.
United States Provisional Patent Application filed December 3, 2002 serial number 60/430,732 entitled ' Polyvalent, Primary HIV-1 Envelope Glycoprotein DNA Vaccine.
United States Provisional Patent Application filed in September 2003, serial number 60/503/907 entitled 'Polyvalent DNA and Protein Vaccines.'
United States Utility Patent Application filed December 3, 2003 and its foreign counterparts referred to by the parties as the Joint Patent Filing.
Licensed Product means the HIV Vaccine and any product that cannot be developed, manufactured, used, or sold without (a) infringing one or more claims under the Patent Rights, (b) using or incorporating some portion of one or more Biological Materials, or (c) using some portion of the Related
Technology.
Biological Materials means certain tangible biological materials that are necessary for the effective exercise of the Patent Rights, which materials are described, as well as tangible materials that are routinely produced through use of the original materials, including, for example, any progeny derived from a cell line, monoclonal antibodies produced by hybridoma cells, DNA or RNA replicated from isolated DNA or RNA, recombinant proteins produced through use of isolated DNA or RNA, and substances routinely purified from a source material included in the original materials (such as recombinant proteins isolated from a cell extract or supernatant by non-proprietary affinity purification methods). These Biological Materials shall be listed on this agreement, which will be periodically amended to include any additional Biological Materials that Medical School may furnish to Company.
Licensor Related Technologies means any additional technologies outside of the 03-24 Technology and the 03-111 Technology that satisfies all of the following: (i) are now or subsequently owned or licensed to Licensor, including any technologies that may be acquired by Licensor pursuant to its option for an exclusive license of the Medical School Subcontract, (ii) result from work done by Medical School under the Medical School Subcontract for a DNA-based HIV vaccine with protein boost, and (iii) are deemed necessary or advantageous by Company for the development or commercialization of the HIV Vaccine.
The '03-111 Technology – U. S. Patent Application Serial Number 60/503,907 (the '03-111 Patent Filing') covering an HIV protein boost technology invention referred to by Medical School and Licensor as UMMC 03-111.
The '03-24 Technology – UMMC 03-24 entitled Primary and Polyvalent HIV-1 Envelope Glycoprotein DNA Vaccines
IPSCIO Record ID: 223153
IPSCIO Record ID: 230759
A Licensed Process is any process which is covered in whole or in part by an issued, unexpired claim or a pending claim contained in the Patent Rights; or, Patent Rights; or, is derived from Patent Rights or know-how, and related to or described in is sold, manufactured or used in any country under this Agreement.
A Licensed Product shall mean any product or part thereof which is covered in whole or in part by an issued, unexpired claim or a pending claim contained in the Patent Rights in the country in which any Licensed Products are made, used or sold; or, is manufactured by using a process which is covered in whole or in part by an issued, unexpired claim or a pending claim contained in the Patent Rights in the country in which any Licensed Process is used or in which such product or part thereof is used or sold; or,
is derived from Patent Rights or know-how, and related to or described in Patent Rights.
(a) Human [blood] disorders, [metabolic and congenital]. This field includes human [hematological] diseases that arise due to the absence, over-expression or altered expression of proteins normally (present in blood]. The primary site and location of these proteins is [blood]. Specifically included are human [hemoglobinopathies (i. e. Sickle Cell Anemia and Thalassemia)] and human disorders of the [coagulation metabolism (i.e., Hemophilia A (factor VIII), Von Willebrands Disease (factor VIII) and Hemophilia B (factor IX))]. Specifically excluded are human [neoplasias of the lymphoreticular system (lymphomas, reticuloendothelioses, or plasma cell dyscrasias)].
(b) Human [malignant neoplastic] diseases. This field includes all forms of human (cancer, including but not limited to skin cancers and all solid tumors]. This field also includes all forms of human [cancers of the hematopoietic tissues (the leukemias), Hodgkins Disease and Non-Hodgkins Lymphoma].
c) relating to a syndrome (AIDS) characterized by opportunistic infections occuring as a result of profound
deficiency of the helper – T4 lymphocytes (CD4 lymphocytes). At any time during the life of this Agreement the definition of AIDs shall be that definition currently in use by the Centers for Disease Control, Atlanta, Georgia].
(d) All human [infectious diseases other than HIV]. This Field includes: [human viral diseases (besides HIVs, human bacterial, yeast and other microorganism based diseases, and all other human infectious diseases.